These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15006954)

  • 1. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
    Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
    Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis.
    Wilson R; Jones P; Schaberg T; Arvis P; Duprat-Lomon I; Sagnier PP;
    Thorax; 2006 Apr; 61(4):337-42. PubMed ID: 16449273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
    Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R
    Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
    Schaberg T; Möller M; File T; Stauch K; Landen H
    Clin Drug Investig; 2006; 26(12):733-44. PubMed ID: 17274680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
    Chodosh S; DeAbate CA; Haverstock D; Aneiro L; Church D
    Respir Med; 2000 Jan; 94(1):18-27. PubMed ID: 10714475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.
    Wilson R; Anzueto A; Miravitlles M; Arvis P; Faragó G; Haverstock D; Trajanovic M; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2011; 6():373-83. PubMed ID: 21760724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
    Llor C; Naberan K; Cots JM; Molina J; Miravitlles M
    Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
    Wilson R; Anzueto A; Miravitlles M; Arvis P; Alder J; Haverstock D; Trajanovic M; Sethi S
    Eur Respir J; 2012 Jul; 40(1):17-27. PubMed ID: 22135277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
    Miravitlles M; Llor C; Naberan K; Cots JM; Molina J;
    Respir Med; 2005 Aug; 99(8):955-65. PubMed ID: 15950136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
    Anzueto A; Miravitlles M; Ewig S; Legnani D; Heldner S; Stauch K
    Respir Med; 2012 Sep; 106(9):1258-67. PubMed ID: 22749710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
    Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
    Weiss LR
    Clin Ther; 2002 Sep; 24(9):1414-25. PubMed ID: 12380633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
    Wilson R; Schentag JJ; Ball P; Mandell L;
    Clin Ther; 2002 Apr; 24(4):639-52. PubMed ID: 12017408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
    Wilson R; Langan C; Ball P; Bateman K; Pypstra R;
    Respir Med; 2003 Mar; 97(3):242-9. PubMed ID: 12645831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).
    Chuchalin A; Zakharova M; Dokic D; Tokić M; Marschall HP; Petri T
    BMC Pulm Med; 2013 Jan; 13():5. PubMed ID: 23343427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group.
    Burke T; Villanueva C; Mariano H; Huck W; Orchard D; Haverstock D; Heyd A; Church D
    Clin Ther; 1999 Oct; 21(10):1664-77. PubMed ID: 10566563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
    Wilson R; Kubin R; Ballin I; Deppermann KM; Bassaris HP; Leophonte P; Schreurs AJ; Torres A; Sommerauer B
    J Antimicrob Chemother; 1999 Oct; 44(4):501-13. PubMed ID: 10588312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.